Boenning & Scattergood’s Biogen BIIB Stock Holding History

Boenning & Scattergood’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-760	Closed	-$203K	–	403
2022 Q3	$203K	Buy	+760	New	+$161K	0.04%	349
2021 Q4	–	Sell	-760	Closed	-$215K	–	392
2021 Q3	$215K	Sell	760 -100	-12%	-$32.8K	0.04%	350
2021 Q2	$298K	Sell	860 -329	-28%	-$99.7K	0.05%	308
2021 Q1	$333K	Buy	1,189 +294	+33%	+$79.3K	0.06%	281
2020 Q4	$219K	Sell	895 -35	-4%	-$9.03K	0.05%	312
2020 Q3	$264K	Buy	930 +60	+7%	+$16.7K	0.06%	269
2020 Q2	$233K	Sell	870 -100	-10%	-$30.1K	0.06%	274
2020 Q1	$307K	Hold	970	–	–	0.11%	198
2019 Q4	$288K	Buy	970 +70	+8%	+$19.4K	0.07%	247
2019 Q3	$210K	Hold	900	–	–	0.06%	253
2019 Q2	$211K	Hold	900	–	–	0.06%	257
2019 Q1	$212K	Buy	900 +200	+29%	+$63K	0.06%	265
2018 Q4	$211K	Sell	700 -100	-13%	-$31.9K	0.07%	241
2018 Q3	$282K	Sell	800 -530	-40%	-$182K	0.09%	221
2018 Q2	$386K	Buy	+1,330	New	+$374K	0.13%	192

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Boenning & Scattergood's BIIB Position: Q4 2022 in Review

Boenning & Scattergood sold out of Biogen (BIIB) in Q4 2022, closing a stake of 760 shares — an estimated $203K sold.

Boenning & Scattergood first reported a position in BIIB in Q2 2018 and held it in 15 quarters. The position peaked at $386K in Q2 2018. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Boenning & Scattergood reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Boenning & Scattergood sold 760 Biogen shares in Q4 2022, an estimated $203K.
Boenning & Scattergood first reported a position in Biogen in Q2 2018 and held it in 15 quarters.
Boenning & Scattergood's Biogen position peaked at $386K in Q2 2018.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Boenning & Scattergood's 13F filing for Q4 2022, filed 26 Jan 2023.